News & Research
New studies, trials, regulatory changes and news about the compounds on Amino WRX. Items are collected automatically once a day and summarised by AI; they are not reviewed by an editor before they appear here. Read the original source before relying on anything.
Last updated 2026-10-17.
- ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease (not yet recruiting)
ClinicalTrials.gov
ELEVATE-LIVER, a not-yet-recruiting trial, will test whether survodutide improves heart structure and function in people with overweight or obesity and fatty liver disease. No results are available because recruitment has not started.
- An Intermediate Size Expanded Access Protocol of Elamipretide (available)
ClinicalTrials.gov
An intermediate-size expanded access protocol for elamipretide is listed as available. Expanded access can allow some patients to receive a drug outside ordinary marketing approval and is not an efficacy result.
- A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (completed)
ClinicalTrials.gov
A trial comparing orforglipron with dapagliflozin in adults with type 2 diabetes already on metformin is listed as completed. This registry entry does not report efficacy or safety results.
- Thymosin-α1 for Recurrent Implantation Failure
ClinicalTrials.gov
A clinical trial of thymosin alpha-1 for recurrent implantation failure is recruiting. It is early human research in a fertility setting and has not reported results.
- SYNCHRONIZE-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
ClinicalTrials.gov
A not-yet-recruiting trial, SYNCHRONIZE-HERA, will test survodutide for weight loss in women with overweight or obesity who are in menopause or have finished it. No results are available because enrollment has not started.
- A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
ClinicalTrials.gov
A recruiting trial is testing whether survodutide helps people with type 2 diabetes control blood sugar. Results have not been posted.
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) (recruiting)
ClinicalTrials.gov
ATTAIN-Outcomes is a recruiting trial of oral orforglipron on cardiovascular outcomes in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease. Heart and kidney outcome data for orforglipron are not yet available from this record.
- Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency (recruiting)
ClinicalTrials.gov
A phase 3 trial of LUM-201, the oral growth hormone secretagogue also known as ibutamoren (MK-677), is recruiting children with growth hormone deficiency. It is a large human efficacy and safety study of this compound, in children rather than adults.
- Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity (recruiting)
ClinicalTrials.gov
A recruiting trial is testing whether mazdutide changes coronary plaque in people with coronary atherosclerosis and overweight or obesity. It extends human study of mazdutide to a cardiovascular imaging outcome, but results are not yet available.
- Trialretatrutide2026-10-08The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) (active not recruiting)
ClinicalTrials.gov
TRIUMPH-Outcomes is testing once-weekly retatrutide for cardiovascular and kidney outcomes in adults living with obesity. The trial is active and no longer recruiting, and this registry update does not report results.
- Thymalfasin for Immune Recovery in Adults With Sepsis (recruiting)
ClinicalTrials.gov
A recruiting trial is studying thymalfasin, another name for thymosin alpha-1, for immune recovery in adults with sepsis. It is new human research on this peptide in critical illness, with no results reported yet.
- Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (recruiting)
ClinicalTrials.gov
A recruiting trial is evaluating the efficacy and safety of orforglipron in people with peripheral artery disease. It moves human testing of this oral GLP-1 receptor agonist into a vascular-disease population, without results yet.
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee (active not recruiting)
ClinicalTrials.gov
A trial of orforglipron in people with obesity or overweight and knee osteoarthritis is active and no longer recruiting. It is testing the drug in a joint-disease population, and this update does not include results.
- A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity (recruiting)
ClinicalTrials.gov
A recruiting trial is testing orforglipron in people with overweight who are at risk of obesity-related complications or of progressing to class 1 obesity. It looks at earlier use, before established obesity, and has not reported results.
- A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems (not yet recruiting)
ClinicalTrials.gov
A trial of orforglipron in Chinese participants with obesity or overweight and weight-related health problems is registered but not yet recruiting. It is meant to produce population-specific human data that are still missing.
- A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (recruiting)
ClinicalTrials.gov
A recruiting trial is testing orforglipron in women who have stress urinary incontinence and obesity or overweight. It asks whether treatment in this group affects a symptom that often tracks with weight, and results are pending.
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting (recruiting)
ClinicalTrials.gov
A recruiting trial is studying orforglipron in people with type 2 diabetes who observe Ramadan fasting. It should clarify use during prolonged daily fasting, which standard obesity trials do not address, and results are not in yet.
- Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD (recruiting)
ClinicalTrials.gov
A recruiting study is measuring visceral fat and liver changes in people with chronic kidney disease who receive semaglutide. No outcomes are available yet, so this is a trial start rather than new evidence of benefit or harm.
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (active not recruiting)
ClinicalTrials.gov
A ClinicalTrials.gov record lists a cagrilintide weight-loss study in adults with overweight or obesity and type 2 diabetes as active but not recruiting. No results are posted, so the record shows the trial is underway rather than what weight change it produced.
- Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes (active not recruiting)
ClinicalTrials.gov
An active trial is comparing once-weekly ribupatide with semaglutide and placebo in people with obesity who do not have diabetes. Efficacy and safety results have not been released.
- A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus (active not recruiting)
ClinicalTrials.gov
An ongoing trial is measuring how retatrutide affects insulin secretion and insulin sensitivity in adults with type 2 diabetes. No results have been released, so its effect on insulin function is not yet known.
- The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity (recruiting)
ClinicalTrials.gov
A recruiting trial is testing tirzepatide for menopausal hot flashes and markers of biological aging in postmenopausal women with obesity. No results are available, so any benefit for those symptoms is unproven.
- GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes (recruiting)
ClinicalTrials.gov
A recruiting study is examining GLP-1 receptor agonist use and sarcopenia in people with obesity who do not have diabetes. It has not reported results, so this listing does not establish a link with muscle loss.
- The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial (active not recruiting)
ClinicalTrials.gov
A placebo-controlled trial is testing how oral semaglutide affects bone turnover in people with type 2 diabetes. Results are not yet available, so effects on bone remain unknown.
- A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) (completed)
ClinicalTrials.gov
The survodutide cardiovascular outcomes trial, SYNCHRONIZE-CVOT, is listed as completed. This registry update does not include results, so no cardiovascular benefit or harm should be claimed from the status change alone.
- LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis (recruiting)
ClinicalTrials.gov
The LIVERAGE trial of survodutide in MASH with moderate or advanced fibrosis is recruiting. Readers should see this as ongoing human research, not as evidence that survodutide treats liver fibrosis.
- LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis (recruiting)
ClinicalTrials.gov
A companion LIVERAGE trial of survodutide in MASH with cirrhosis is recruiting. The page should separate this higher-risk ongoing study from any claim of benefit in advanced liver disease.
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight (recruiting)
ClinicalTrials.gov
A trial is recruiting children and adolescents with excess body weight to test cagrilintide and CagriSema. The site should say these products are not established for minors and that this is a pharmaceutical trial, not a reason to use research material in children.
- SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight (not yet recruiting)
ClinicalTrials.gov
SYNCHRONIZE-START, a survodutide weight-loss trial in people with overweight or obesity without diabetes, is listed as not yet recruiting. The page should not describe that non-diabetes phase 3 study as enrolled or completed.